Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Inclusion Criteria: * Males and females between the ages of 18 and 75 who are diagnosed with mild to moderate Crohn's disease (defined by a CDAI \[Crohn's Disease Activity Index\] score of 220 and 450) * Normal lab parameters * Are willing to give informed consent * Have previously used and either were intolerant to or lost response to infliximab Exclusion Criteria: * History of certain types of cancer * Diagnosis of ulcerative colitis * Pregnant female or breast feeding subjects * Known obstructive strictures * Surgical bowel resection in the past 6 months * History of listeria, human immunodeficiency virus (HIV), central nervous system demyelinating disease or untreated TB (tuberculosis) * History of poorly controlled medical conditions * Specific doses and durations of Crohn's medications * Subjects that have previously used infliximab and have never clinically responded unless primary non-response was due to a treatment limiting reaction to infliximab